Reaching cardiovascular prevention guideline targets with a polypill-based approach: A meta-analysis of randomised clinical trials
Selak, Vanessa; Webster, Ruth; Stepien, Sandrine; Bullen, Chris; Patel, Anushka; Thom, Simon; Arroll, Bruce; Bots, Michiel L.; Brown, Alex; Crengle, Sue; Dorairaj, Prabhakaran; Elley, C. Raina; Grobbee, Diederick E.; Harwood, Matire; Hillis, Graham S.; Laba, Tracey Lea; Neal, Bruce; Peiris, David; Rafter, Natasha; Reid, Christopher; Stanton, Alice; Tonkin, Andrew; Usherwood, Tim; Wadham, Angela; Rodgers, Anthony
(2019) Heart, volume 105, issue 1, pp. 42 - 48
(Article)
Abstract
Objective: The aim of this study was to determine the effect of polypill-based care on the achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood pressure (BP), low-density lipoprotein (LDL) cholesterol and antiplatelet therapy. Methods: We conducted an individual participant data meta-analysis of three randomised clinical trials
... read more
that compared a strategy using a polypill containing aspirin, statin and antihypertensive therapy with usual care in patients with a prior cardiovascular disease (CVD) event or who were at high risk of their first event. Overall, the trials included 3140 patients from Australia, England, India, Ireland, the Netherlands and New Zealand (75% male, mean age 62 years and 76% with a prior CVD event). The primary outcome for this study was the proportion of people achieving ESC guideline targets for BP, LDL and antiplatelet therapy. Results: Those randomised to polypill-based care were more likely than those receiving usual care to achieve recommended targets for BP (62% vs 58%, risk ratio (RR) 1.08, 95% CI 1.02 to 1.15), LDL (39% vs 34%, RR 1.13, 95% CI 1.02 to 1.25) and all three targets for BP, LDL and adherence to antiplatelet therapy (the latter only applicable to those with a prior CVD event) simultaneously (24% vs 19%, RR 1.27, 95% CI 1.10 to 1.47) at 12 months. There was no difference between groups in antiplatelet adherence (96% vs 96%, RR 1.00, 95% CI 0.98 to 1.01). There was heterogeneity by baseline treatment intensity such that treatment effects increased with the fewer the number of treatments being taken at baseline: for patients taking 3, 2 and 0-1 treatment modalities the RRs for reaching all three guideline goals simultaneously were 1.10 (95% CI 0.94 to 1.30, 22% vs 20%), 1.62 (95% CI 1.09 to 2.42, 27% vs 17%) and 3.07 (95% CI 1.77 to 5.33, 35% vs 11%), respectively. Conclusions: Polypill-based therapy significantly improved the achievement of all three ESC targets for BP, LDL and antiplatelet therapy compared with usual care, particularly among those undertreated at baseline.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: cardiac risk factors and prevention, Cardiology and Cardiovascular Medicine
ISSN: 1355-6037
Publisher: BMJ Publishing Group
Note: Funding Information: Funding rW is funded by an nhMrc early career fellowship. the authors have received grants from several research charities and national funding agencies for research on cardiovascular polypills, and from Dr reddy’s laboratories for coordination of the sPace program (www.spacecollaboration.org). the polypills used in the sPace trials were manufactured and supplied by Dr reddy’s laboratories free of charge. some authors received funding from Dr reddy’s laboratories to attend investigator meetings related to the polypill (Vs, rW, aP, st, cre, nr, aW, ar). all authors are independent from trial funders. all authors accept full responsibility for the conduct of the study, had access to the data and controlled the decision to publish. Funding Information: Competing interests support for the submitted work: rW is funded by an nhMrc early career fellowship. the authors have received grants from several research charities and national funding agencies for research on cardiovascular polypills, and from Dr reddy’s laboratories for coordination of the sPace programme (www.spacecollaboration.org). the polypills used in the sPace trials were manufactured and supplied by Dr reddy’s laboratories free of charge. some authors received funding from Dr reddy’s laboratories to attend investigator meetings related to the polypill (Vs, rW, aP, st, nr, aW and ar). george health enterprises, the social enterprise arm of the george institute for global health (employer of some coauthors) has received investment for the development of fixed dose combination therapy containing statin, aspirin and blood pressure lowering medications. Publisher Copyright: © © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
(Peer reviewed)